You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 140 No. 4, April 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  Review Article
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (5)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Surgical Physiology, Other
 •Review
 •Alert me on articles by topic

Surgical Implications of Ischemic Preconditioning

Shanker Pasupathy, FRCS; Shervanthi Homer-Vanniasinkam, FRCS

Arch Surg. 2005;140:405-409.

Background  Ischemic preconditioning (IP) has emerged as a powerful experimental method of ameliorating ischemic injury in a variety of organs. This systematic review examines the surgical implications of this phenomenon.

Data Source  A MEDLINE search was conducted to identify laboratory and clinical studies investigating IP-induced protection in a variety of organ systems. Particular emphasis was placed on uncovering evidence for the use of IP in the surgical setting.

Data Synthesis  Human clinical trials using IP have been successfully carried out in the fields of cardiac, hepatic, and pulmonary surgery. Epidemiologic data exist to support the existence of IP-induced neuroprotection in humans. Human skeletal muscle has been preconditioned experimentally, as have human proximal tubule (renal) cells. At present, there is no evidence for IP occurring in the human intestine, although animal studies attest to the possibility. Ischemic preconditioning appears to be effective even when applied to a site remote to the organ exposed to ischemia. However, these favorable effects are less evident in diabetic and elderly patients.

Conclusion  Ischemic preconditioning is safe for use in elective cardiac, hepatic, and pulmonary surgery. More studies with greater patient numbers need to be carried out in these areas to demonstrate the efficacy of IP in providing clinical benefit in terms of reducing morbidity and mortality. Although laboratory and experimental evidence is favorable, clinical studies using IP in orthopedic, vascular, reconstructive, transplantation, and gastrointestinal surgery are lacking.


Author Affiliations: Vascular Surgical Unit, The General Infirmary at Leeds, England.


RELATED ARTICLE

Surgical Implications of Ischemic Preconditioning—Invited Critique
Jeffrey B. Matthews
Arch Surg. 2005;140(4):410.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Increased C reactive protein and cardiac enzyme levels after coronary stent implantation. Is there protection by remote ischaemic preconditioning?
Iliodromitis et al.
Heart 2006;92:1821-1826.
ABSTRACT | FULL TEXT  

Preconditioning, postconditioning and their application to clinical cardiology
Kloner and Rezkalla
Cardiovasc Res 2006;70:297-307.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.